ABIVAX SA

Abivax SA (ABVX, CUSIP 00370M103) entered Q1 2026 with $5.4B of institutional 13F value across 237 institutional holders — a holder profile appropriate for a biotechnology company whose lead asset (obefazimod/ABX464) is in late-stage development for moderate-to-severe ulcerative colitis and Crohn's disease, and whose European-regulatory and clinical-readout timeline drives institutional positioning. The defining Q1 signals are diverging: Point72 Asset Management reduced its ABVX position by $320M, representing either a thesis reduction around clinical-readout uncertainty or a risk-management rotation within a concentrated biotech book, while Logos Global Management added $21M in what appears to be a new position or build at the conviction level. The 237-holder base distributes across European-biopharma, thematic-biotech, and crossover fundamental managers, and the $5.4B aggregate reflects the stage-adjusted valuation typical of late-clinical-stage European biotechs with a differentiated mechanism in a large inflammatory bowel disease (IBD) market opportunity. For smart-money trackers, ABVX's Q1 rotation pattern between concentration-reducing large quantamental players and conviction-building specialists is the diagnostic worth surfacing.